Vanguard Fiduciary Trust
VRDN icon

Vanguard Fiduciary Trust’s Viridian Therapeutics VRDN Stock Holding History

Vanguard Fiduciary Trust’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1M Buy
657,588
+66,363
+11% +$1.07M ﹤0.01% 1708
2026
Q1 		$11.6M Buy
+591,225
New +$17.6M ﹤0.01% 1638

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Fiduciary Trust's VRDN Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Viridian Therapeutics (VRDN) stake by 11% in Q2 2026, buying an estimated $1.07M and bringing the position to 657,588 shares worth $12.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1708.

Vanguard Fiduciary Trust first reported a position in VRDN in Q1 2026 and has held it in 2 quarters since. 213 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Vanguard Fiduciary Trust held 657,588 shares of Viridian Therapeutics worth $12.1M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 66,363 Viridian Therapeutics shares in Q2 2026, an estimated $1.07M.
  • Viridian Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1708 holding.
  • Vanguard Fiduciary Trust first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 213 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.